ROIV
Roivant Sciences Ltd.
NASDAQ · GBHealthcareBiotechnology
$34.05-1.33%
Price as of Jul 20, 2026
ROIV financials
Roivant Sciences Ltd. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $8.3M | $29.1M | $32.7M | $31.5M |
| Cost of revenue | $1.3M | $911.0K | $1.6M | $3.0M |
| Gross profit | $7.0M | $28.1M | $31.1M | $28.5M |
| Operating expenses | $1.3B | $1.1B | $856.0M | $837.5M |
| Operating income | -$1.3B | -$1.1B | -$824.9M | -$809.0M |
| Net income | -$299.8M | -$172.0M | $4.3B | -$1.0B |
| EBITDA | -$261.2M | -$667.5M | $4.6B | -$838.2M |
| Basic EPS | $-0.43 | $-0.24 | $5.55 | $-1.42 |
| Diluted EPS | $-0.43 | $-0.24 | $5.23 | $-1.42 |
| Balance sheet | ||||
| Cash & equivalents | $1.4B | $2.7B | $6.5B | $1.7B |
| Total assets | $5.7B | $5.4B | $7.2B | $2.4B |
| Total liabilities | $435.6M | $249.7M | $774.0M | $782.0M |
| Stockholders’ equity | $4.5B | $4.7B | $6.0B | $1.2B |
| Total debt | $107.4M | $100.2M | $499.7M | $481.4M |
| Net debt | -$1.3B | -$2.6B | -$6.0B | -$1.2B |
| Cash flow | ||||
| Operating cash flow | -$750.3M | -$839.5M | -$765.3M | -$843.4M |
| Capital expenditure | -$8.2M | -$4.6M | -$1.4M | -$12.7M |
| Free cash flow | -$758.6M | -$844.0M | -$766.6M | -$856.1M |
| Dividends paid | $0.00 | $0.00 | -$6.0M | $0.00 |
| Share repurchases | -$319.5M | -$1.3B | $0.00 | $0.00 |